Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2007.15.4989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Berberine attenuates sunitinib-induced cardiac dysfunction by normalizing calcium regulation disorder via SGK1 activation.
Food Chem Toxicol
May 2023
Department of Pharmacy, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, China. Electronic address:
Sunitinib (SNT)-induced cardiotoxicity is associated with abnormal calcium regulation caused by phosphoinositide 3 kinase inhibition in the heart. Berberine (BBR) is a natural compound that exhibits cardioprotective effects and regulates calcium homeostasis. We hypothesized that BBR ameliorates SNT-induced cardiotoxicity by normalizing the calcium regulation disorder via serum and glucocorticoid-regulated kinase 1 (SGK1) activation.
View Article and Find Full Text PDFSunitinib-Induced Acute Liver Failure.
Case Rep Gastroenterol
January 2021
Department of Gastroenterology, Staten Island University Hospital, New York, New York, USA.
Drug-induced liver injury is an uncommon but life-threatening entity. Sunitinib is a tyrosine kinase inhibitor used for advanced and imatinib-refractory gastrointestinal stromal tumors. It causes transient elevation in liver enzymes.
View Article and Find Full Text PDFDownregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib.
Front Pharmacol
August 2019
Department of Pharmacology, Hebei Medical University, The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Province, The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Shijiazhuang, China.
The main adverse effect of tyrosine kinase inhibitors, such as sunitinib, is cardiac contractile dysfunction; however, the molecular mechanisms of this effect remain largely obscure. MicroRNAs (miRNAs) are key regulatory factors in both cardiovascular diseases and the tyrosine kinase pathway. Therefore, we analyzed the differential expression of miRNAs in the myocardium in mice after exposure to sunitinib using miRNA microarray.
View Article and Find Full Text PDFUpregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
Arch Toxicol
June 2019
Department of Pharmacology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Sunitinib (SNT) is a multi-targeted receptor tyrosine kinase inhibitor that has been approved by the FDA for cancer therapy. However, its cardiotoxicity has limited the clinical applicability with no effective therapeutic approach available. As a broadband kinase inhibitor, the function of several kinases that are essential to cardiac function might also be affected by SNT, such as calmodulin-dependent protein kinase (CaMKII), cyclic-AMP-dependent protein kinases (PKA), AMP-activated protein kinase (AMPK), and phosphoinositide 3 kinase (PI3K).
View Article and Find Full Text PDFSunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report.
J Cancer Res Ther
September 2018
Department of Radiotherapy, R. G. Kar Medical College and Hospitals, Kolkata, West Bengal, India.
Thyroid abnormalities are found nearly 70% cases receiving sunitinib therapy. Mostly, patients suffer transient hypothyroidism rarely presents with overt acute symptoms requiring levothyroxine replacement. Onset is variable in published literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!